What is the patient's current coagulation status and treatment plan for coagulopathy, and what is the assessment and plan for the patient's oliguria and potential nephropathy?

Coagulopathy Management

Last Laboratory Results

The progress note does not document the most recent coagulation studies. This is a critical oversight for a patient with documented coagulopathy secondary to polycythemia vera from cyanotic heart disease 1. Essential baseline coagulation parameters that should have been obtained include:

• Prothrombin Time (PT)/INR - most sensitive for monitoring vitamin K therapy 1
• Activated Partial Thromboplastin Time (aPTT)
• Platelet count - target >50 × 10⁹/L in bleeding patients 1
• Fibrinogen level - target >1.5 g/L in hemorrhage settings 1
• Complete blood count with hemoglobin - to assess for ongoing blood loss 1

Fresh Frozen Plasma Transfusions Given

The patient received a total of 8 units of Fresh Frozen Plasma (FFP):

• 2 units on 10/16/25 (day of first surgery - burr hole craniectomy)
• 2 units on 10/17/25 (post-operative day 1 from first surgery)
• 4 units on 11/11/25 (day of second surgery - craniotomy and abscess excision)

These transfusions were appropriately timed around surgical procedures to prevent dilutional and consumptive coagulopathy 1.

Plan to Repeat Coagulation Labs

No specific plan for repeat coagulation monitoring is documented in this progress note. This represents a significant gap in management. For a post-operative patient on vitamin K therapy with documented coagulopathy, coagulation parameters should be monitored every 6-8 hours initially, then daily once stable 1. The PT/INR should be checked regularly to guide vitamin K dosing and assess response 2.

Immediate action required: Order PT/INR, aPTT, platelet count, fibrinogen, and hemoglobin stat, then establish a monitoring schedule of every 6-8 hours for the first 24-48 hours post-operatively 1.

Duration and Type of Vitamin K Therapy

Type of Vitamin K

The patient is receiving Vitamin K1 (Phytonadione) - this is the correct formulation 2. Vitamin K1 is the only form used clinically for correcting coagulopathy:

• Vitamin K1 (Phytonadione): Natural form, used therapeutically
• Vitamin K2: Produced by gut bacteria, not used therapeutically
• Vitamin K3 (Menadione): Synthetic, not used due to toxicity

The current dose of 5 mg IV every 8 hours is appropriate for anticoagulant-induced prothrombin deficiency, though the FDA label suggests initial doses of 2.5-10 mg with up to 25 mg in severe cases 2.

Duration of Vitamin K Therapy

Vitamin K should be continued until:

1. PT/INR normalizes (PT ratio <1.5, which is NOT the same as INR) 1, 2
2. Clinical bleeding risk resolves - at minimum 48-72 hours post-operatively with stable coagulation parameters 1
3. Coagulation factors synthesize adequately - requires minimum 1-2 hours for measurable improvement, with full effect taking 6-8 hours 2

Specific recommendation: Continue vitamin K for at least 3-5 days post-operatively or until PT normalizes and remains stable for 24 hours off therapy 2. Monitor PT/INR 6-8 hours after each dose initially 2. If PT has not shortened satisfactorily in 6-8 hours, the dose should be repeated 2.

Critical caveat: Failure to respond to vitamin K may indicate the condition is inherently unresponsive (such as severe liver dysfunction from chronic cyanotic heart disease), and repeated large doses are not warranted 2. The patient's underlying polycythemia vera and chronic hypoxemia may impair hepatic synthesis of clotting factors despite adequate vitamin K 2.

---

Nephropathy and Oliguria Assessment

Etiology of Oliguria

This patient's oliguria (0.44 cc/kg/hr, below the threshold of 0.5 cc/kg/hr) is multifactorial:

Primary Cause: Hypovolemia

The clinical picture strongly suggests prerenal azotemia from inadequate fluid intake:

• Minimal oral intake: Only 50 cc in 24 hours
• Physical examination findings: Dry oral mucosa, dry lips, mild sunken eyeballs, pale conjunctivae 3
• Positive fluid balance misleading: The +380 cc balance includes 700 cc of medications, suggesting actual free water intake is inadequate

Contributing Factor: Cyanotic Nephropathy

Chronic cyanotic heart disease causes progressive renal dysfunction through:

• Chronic hypoxemia (O2 sat 79% on room air) leading to renal hypoperfusion 3, 4
• Polycythemia-induced hyperviscosity reducing renal blood flow 5
• Glomerular microthrombi from hypercoagulable state 5, 6

Distinguishing Prerenal from Intrinsic Renal Oliguria

The patient requires immediate assessment with:

• Urine sodium concentration - expect <20 mEq/L if prerenal 3
• Fractional excretion of sodium (FENa) - expect <1% if prerenal 3
• Urine osmolality - expect >500 mOsm/kg if prerenal 3
• Renal failure index - expect <1 if prerenal 3

In critically ill patients, hypovolemic oliguria responds to fluid challenge (500 mL bolus increasing urine output to >0.5 mL/kg/hr), while normovolemic oliguria does not 3.

Latest Kidney-Related Laboratory Results

No recent renal function tests are documented in this progress note. This is unacceptable for a patient with known cyanotic nephropathy and new-onset oliguria. Essential labs that should have been obtained include:

• Serum creatinine and BUN - to calculate baseline renal function
• Serum electrolytes (sodium, potassium, chloride, bicarbonate) - to assess for electrolyte derangements
• Serum osmolality - to calculate osmolar gap
• Urinalysis with microscopy - to assess for casts, proteinuria, hematuria
• Urine sodium, osmolality, and creatinine - to calculate FENa and renal failure index 3

Edema Assessment

No edema is present on physical examination:

• No periorbital edema documented
• No peripheral edema in extremities
• No pulmonary edema (clear breath sounds, no rales)
• No ascites (flat abdomen, normoactive bowel sounds)

This absence of edema despite oliguria strongly supports prerenal azotemia from hypovolemia rather than intrinsic renal failure 3, 4. Patients with acute kidney injury and fluid overload typically develop edema, pulmonary congestion, and cardiopulmonary complications 4.

Plan for Laboratory Monitoring

Immediate actions required:

1. Stat labs: Serum creatinine, BUN, electrolytes, serum osmolality, urinalysis with microscopy, urine sodium, urine osmolality, urine creatinine 3

2. Fluid challenge test: Administer 500 mL normal saline bolus over 30 minutes and reassess urine output 3. If urine output increases to >0.5 mL/kg/hr, diagnosis is prerenal azotemia from hypovolemia 3.

3. Ongoing monitoring schedule:

   • Urine output: Hourly (already being done)
   • Serum creatinine and electrolytes: Every 12-24 hours until stable
   • Daily weights: To assess fluid status accurately
   • Strict intake/output: Continue current practice but increase oral fluid intake aggressively - target at least 1000-1500 mL/day orally if tolerated

4. Adjust IV fluid rate: Current rate of 35 cc/hr (840 cc/day) plus 50 cc oral intake totals only 890 cc/day of free water, which is grossly inadequate for a 35.9 kg patient (should be approximately 1400-1800 mL/day maintenance). Increase IV fluid rate to 50-60 cc/hr and encourage oral intake 3, 4.

Critical monitoring caveat: In patients with cyanotic heart disease and baseline renal dysfunction, oliguria may represent appropriate renal response to decreased effective circulating volume despite adequate total body water 3. However, the physical examination findings of dehydration (dry mucosa, sunken eyes) indicate true hypovolemia requiring aggressive fluid resuscitation 3.